Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 177.52B -26.0% |
| Revenue (ttm) | 43.86B +8.1% |
| Net Income | 16.32B +16.6% |
| EPS | 3.67 +16.8% |
| Shares Out | n/a |
| PE Ratio | 10.88 |
| Forward PE | 14.71 |
| Dividend | 1.57 (3.92%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 123,641 |
| Average Volume | 335,655 |
| Open | 40.22 |
| Previous Close | 39.95 |
| Day's Range | 39.80 - 40.92 |
| 52-Week Range | 30.24 - 71.53 |
| Beta | 0.35 |
| RSI | 69.86 |
| Earnings Date | May 6, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk (NVO) Expected to See Significant Upside Potential
Novo Nordisk (NVO) Expected to See Significant Upside Potential
Is Novo Nordisk's Rebound for Real--or Just a Head Fake?
Novo Nordisk recently posted strong quarterly results. Newer launches are boosting sales.
Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026
Almost a third of adults taking Wegovy® pill (oral semaglutide 25 mg) were early responders to treatment, achieving an average of 13.2% weight loss after four months and 21.6% weight loss at the end o...
Mixed options sentiment in Novo Nordisk with shares up 1.26%
Mixed options sentiment in Novo Nordisk (NVO), with shares up 58c, or 1.26%, near $46.98. Options volume relatively light with 44k contracts traded and calls leading puts for a put/call…
NVO: Novo Nordisk Highlights Wegovy's Impact on Weight Loss Among Women
NVO: Novo Nordisk Highlights Wegovy's Impact on Weight Loss Among Women
Novo Nordisk price target raised to DKK 290 from DKK 275 at Citi
Citi raised the firm’s price target on Novo Nordisk (NVO) to DKK 290 from DKK 275 and keeps a Neutral rating on the shares.
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
Analysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.
Novo Nordisk updates on Wegovy results in women across menopause stages
The company states: “Novo Nordisk (NVO) today announced data demonstrating that Wegovy (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity ac...
NVO: Novo Nordisk Shares Rise on Positive Wegovy Weight Loss Data
NVO: Novo Nordisk Shares Rise on Positive Wegovy Weight Loss Data
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 12 May 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons ...
Healthy Returns: Novo Nordisk says high-dose Wegovy helped some patients lose nearly 28% of their weight
Novo Nordisk released new data that could help boost the case for the higher dose version of its blockbuster obesity injection Wegovy.
Novo Nordisk (NVO) Reports Promising Weight Loss Results from Higher Dose Wegovy
Novo Nordisk (NVO) Reports Promising Weight Loss Results from Higher Dose Wegovy
Hims & Hers plummets 16% after first-quarter loss, weak earnings guidance
Hims & Hers reached a deal with Novo Nordisk in March to sell its GLP-1 weight loss drug Wegovy on its platform.
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1. Substantial weight loss was consistent across all m...
Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight
The company said the majority of the weight loss—around 84%—came from losing body fat while preserving muscle function and improving muscle health.
Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity
Early responders (15% or more weight loss after 24 weeks) to the higher dose of Wegovy ® (semaglutide 7.2 mg) achieved on average 27.7% mean weight loss at week 72 in the STEP UP trial1 Participants t...
Hims & Hers Health Q1 Earnings Call Highlights
Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusHims & Hers Health (NYSE:HIMS) reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, whi...
NVO: Novo Nordisk Shows Bullish Activity with Stock Uptick
NVO: Novo Nordisk Shows Bullish Activity with Stock Uptick
Bullish flow in Novo Nordisk with shares up 0.68%
Bullish flow in Novo Nordisk (NVO), with shares up 32c, or 0.68%, near $46.38. Options volume roughly in line with average with 72k contracts traded and calls leading puts for…
Novo Nordisk Hands Over Parkinson’s Therapy to AI Startup
Novo Nordisk A/S agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI startup to potentially speed its development.
Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy
Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for Parkinson's disease, the biotech firm said on Monday.
Why Eli Lilly’s Rival Novo Nordisk (NVO) Stock Is Rising Today, 5/11/26
Shares in Novo Nordisk ($NVO), the Danish pharma rival to U.S.-based Eli Lilly ($LLY), rose roughly 3% in Monday’s pre-market trading. This comes as the Wegovy weight-loss drug maker is…
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders?
Eli Lilly and Novo Nordisk dominate the weight loss drug market with their injectable GLP-1 drugs. Both players recently won approval for oral formulations, offering patients a new, convenient option.
Oral Ozempic and Wegovy pills now available for same-day delivery on Amazon
"This has been the best product launch in the last decade that we have seen."